Ex Vivo-activated Human Macrophages Kill Chronic Lymphocytic Leukemia Cells in the Presence of Rituximab: Mechanism of Antibody-dependent Cellular Cytotoxicity and Impact of Human Serum

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

2000 • 2,694 citations

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

2002 • 1,853 citations

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

2005 • 965 citations

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

1999 • 653 citations

The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy

2004 • 632 citations

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

2004 • 622 citations

Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo

2003 • 557 citations

Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy

2005 • 531 citations

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

1998 • 527 citations

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

2001 • 425 citations

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011

2004 • 417 citations

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas

2003 • 355 citations

A potential role of macrophage activation in the treatment of cancer

2002 • 352 citations

Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia

2004 • 346 citations

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

1999 • 286 citations

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

2003 • 213 citations

The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice

2005 • 209 citations

Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.

2003 • 184 citations

Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma

2004 • 163 citations

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma

2002 • 147 citations

Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor.

1990 • 127 citations

Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.

2003 • 109 citations

Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms.

2002 • 69 citations

Human cytokines suppress apoptosis of leukaemic CD5⁺ B cells and preserve expression of bcl‐2

1997 • 64 citations

Intrapleural Infusion of Activated Macrophages and γ-Interferon in Malignant Pleural Mesothelioma

2002 • 60 citations

Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma

1996 • 58 citations

Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas

2004 • 53 citations

The functional properties of Fcγ RI, II and III on myeloid cells: A comparative study of killing of erythrocytes and tumor cells mediated through the different Fc receptors

1989 • 52 citations

Phagocytosis of target particles bearing C3b-IgG covalent complexes by human monocytes and polymorphonuclear leucocytes.

1987 • 47 citations

Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages.

1991 • 41 citations

Beyond immunochemotherapy: Combinations of rituximab with cytokines interferon-α2a and granulocyte-macrophage colony stimulating factor

2002 • 41 citations

Evaluation of the antibody-dependent cytotoxic capabilities of individual human monocytes. Role of Fc gamma RI and Fc gamma RII and the effects of cytokines at the single cell level.

1990 • 37 citations

Adoptive Immunotherapy For Superficial Bladder Cancer With Autologous Macrophage Activated Killer Cells

2002 • 34 citations

Anti-tumor properties of human-activated macrophages produced in large scale for clinical application

2005 • 33 citations

B Cell Complement Receptor 2 Transfer Reaction

2003 • 32 citations

Generation of phagocytic MAK and MAC-DC for therapeutic use

1999 • 30 citations

Concepts in radiotherapy and immunotherapy: Anti-CD20 mechanisms of action and targets

2005 • 23 citations

Advancing Therapy For Chronic Lymphocytic Leukemia–the Role Of Rituximab

2004 • 13 citations

Study of the dependence of human monocytes and macrophages antitumoral properties upon TNF-alpha expression or release.

1990 • 11 citations